Loading...
XKRX
084990
Market cap102mUSD
Jul 09, Last price  
3,715.00KRW
1D
0.41%
1Q
-59.13%
Jan 2017
-96.41%
IPO
-92.27%
Name

Helixmith Co Ltd

Chart & Performance

D1W1MN
XKRX:084990 chart
P/E
—
P/S
59.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.30%
Rev. gr., 5y
-9.37%
Revenues
2.60b
-47.77%
3,888,130,9305,745,711,9307,695,186,3106,844,031,5243,157,908,5933,127,118,8004,454,516,0004,248,299,0002,316,244,0002,799,607,0004,201,623,0004,973,972,0002,598,149,668
Net income
-435m
L-97.19%
-4,632,642,230265,714,850256,981,384-714,455,753-6,495,715,322-28,728,935,734-107,036,905,000-82,856,514,000-70,217,908,000-43,538,298,000-64,088,431,000-15,471,280,000-434,924,370
CFO
-3.07b
L-81.66%
-3,581,993,09011,221,8601,211,270,408-2,384,987,881-1,502,924,112-11,968,544,493-37,540,205,000-41,138,568,000-37,294,151,000-38,971,587,000-25,887,653,000-16,717,494,000-3,066,655,343
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Helixmith Co., Ltd is a biotechnology enterprise focused on discovering and advancing novel biopharmaceutical solutions for human diseases. The company maintains a comprehensive pipeline of innovative biologics and herbal therapies, addressing therapeutic areas like cardiovascular ailments, cancer, and immune system disorders. Its clinical research activities are actively conducted across the United States, South Korea, and China. A cornerstone of its product portfolio is VM202, a groundbreaking DNA-based drug designed for treating both cardiovascular and neurological conditions. Additionally, Helixmith's developmental compounds include VM206, a therapeutic vaccine targeting HER2/neu positive breast or ovarian cancer, and VM501, a re-engineered variant of interleukin 11 aimed at alleviating chemotherapy-induced thrombocytopenia. Its ongoing clinical trials encompass VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. Founded in 1996, the company adopted the name Helixmith Co., Ltd in April 2019, transitioning from its former identity as ViroMed Co., Ltd. The organization's main office is located in Seoul, South Korea.
URL
http://helixmith.com/
IPO date
Dec 29, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT